Tagged with OP

Italy An overview of Italy’s pharma, biotech and medtech sectors by number of companies, production value, R&D investment, and number of employees. Made with Visme Infographic Maker   The Italian companies involved in healthcare, split by specialisation, R&D spend, and turnover Made with Visme Infographic Maker   Italy’s regions and their…

China The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s 2020 reporting, including data on drug approvals for all application types (including Investigational New Drugs (INDs), New Drug Applications (NDAs), and ANDAs), hot topics within new drug approvals for 2020, and reasons…

Global Over the past 12 months, PharmaBoardroom has spoken to the heads of several key regulatory bodies across the world. While the approval processes for COVID-19 vaccines have evidently been top of their priority lists, other key topics discussed included the potential of data and AI to change the drug approval…

Japan Writing in the August edition of DIA’s Global Forum, Kotone Matsuyama of the Nippon Medical School gives a run-through of Japan’s response to the COVID-19 pandemic, from the organisation and communication of the country’s public health apparatus to the rollout of treatments and vaccines and the growing use of remote auditing…

Europe Writing in the August edition of DIA’s Global Forum, Sanofi R&D’s Thomas Kühler outlines the bumpy journey towards the full adoption of Health Technology Assessment (HTA) across Europe.   More than three years ago, in January 2018, the European Commission published a draft Regulation on Health Technology Assessment for the EU.…

China In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric Bouteiller examine the potential impact of China’s revision to its patent law on the country’s domestic biopharma innovation landscape and the ability of breakthrough drugs from MNCs to make it onto the Chinese market. …

USA In his latest PharmaBoardroom piece, John Singer looks at Biogen’s marketing campaign for its new Alzheimer’s drug, extending and linking the controversy to the grander strategic themes reshaping the ‘drug market’ as a whole, including the impact of the internet on cognitive change, the unmet need for a different premise for…

Switzerland Dr Vincent Forster of Versantis, a Swiss biotech aiming to develop a new generation of liver disease therapeutics and diagnostics, introduces the company’s foundation story, proprietary technology, and future development goals.   As a start-up company, we try to work in a very lean and dynamic way with a small…

Global As our thoughts here at PharmaBoardroom turn towards the summer holidays, we are happy to share the five most-read articles from our global contributor network so far in 2021. These thought leadership pieces cover topics as vital and diverse as the latest regulatory updates from China; EU-UK pharma trade; the…

UK Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the importance of clinical research studies run based on mechanism of action, the excitement and concerns around CAR T therapies, and…

USA Patient advocate and regular PharmaBoardroom contributor Monica Weldon examines how healthcare’s data revolution has thus far largely ignored the patient voice and argues for a more inclusive approach to drive better, fairer outcomes.    It is natural to want to be healthy, have healthy children, have the best quality of…

Switzerland Aspen’s European Head Thomas Kerscher explains how the sale of the company’s thrombosis portfolio to Mylan has led to an organisational transformation in Europe with a leaner approach and an exclusive focus on anaesthesia. Kerscher also outlines the South African company’s response to the COVID-19 pandemic amid skyrocketing demand for…